FDA
Arcutis Gets FDA Nod for Topical Foam
Westlake Village-based immunodermatology company Arcutis Biotherapeutics Inc. has received approval from the Food and Drug Administration for a topical foam version of its main drug to treat seborrheic dermatitis in individuals aged 9 and older. The approval, announced last month, marks the first new method of application for a drug to treat seborrheic dermatitis in […]
Arcutis Gets FDA Nod For Dermatitis Cream
Westlake Village-based immune-dermatology company Arcutis Biotherapeutics Inc. has received federal approval to begin marketing its drug to treat a type of dermatitis in children ages 6 to 11. The company had already received approval to market the drug for use in people 12 and over. Separately, the company this month announced a public offering of $100 million […]
Arcutis Gets FDA Nod For Plaque Psoriasis Cream
This article has been revised and corrected from the original version. Westlake Village-based immune-dermatology company Arcutis Biotherapeutics Inc. has received federal approval to begin marketing its drug to treat plaque psoriasis in children ages 6 to 11. The company had already received approval to market the drug for use in people 12 and over. Separately, the […]
Atara Gets FDA Nod to Submit Data
Thousand Oaks-based Atara Biotherapeutics has reached an agreement with the federal Food and Drug Administration that clears the way for the company to submit to the agency clinical trial data for its drug to treat a rare blood cancer. Atara has developed a drug platform comprised of a type of immune cell known as a […]